Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Female Sexual Dysfunction
Interventions
DRUG

Syntocinon Nasalspray

"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."

DRUG

Placebo Nasalspray

"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."

Trial Locations (1)

1090

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, Vienna

Sponsors
All Listed Sponsors
collaborator

Leadiant Biosciences, Inc.

INDUSTRY

lead

Medical University of Vienna

OTHER

NCT02229721 - Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women | Biotech Hunter | Biotech Hunter